NCT00251576

Aggrastat to Zocor (AtoZ) - the Use of Two Approved Drugs to Treat Patients Who Have Experienced Chest Pain or a Heart Attack (0733-180)

A Multicenter, Randomized, Controlled, Double-Blind Trial to Investigate the Clinical Efficacy and Tolerability of Early Treatment With Simvastatin 40 mg Daily for 30 Days, Followed by Simvastatin 80 mg Daily Thereafter in Tirofiban-Treated Acute Coronary Syndrome Patients Who Have Been Randomized to Receive Enoxaparin or Unfractionated Heparin in Conjunction With Aspirin

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 4,497 (actual)
• Sponsor: Organon and Co · Industry
• Sex: All
• Age: 18 Years – 80 Years
• Healthy volunteers: Not accepted

Summary

A-Phase: Evaluating patients with chest pain who are receiving approved drugs, to estimate the effectiveness of one type of blood thinner as compared to another type of blood thinner. Z-Phase: To evaluate early treatment of patients with long term chest pain (using an approved drug for 30 days, followed by an increased dose of the drug) as compared to patients (treated with diet and 4 months placebo followed by diet and approved drug) in patients who have experienced acute chest pain or heart attack.

Conditions

• Acute Coronary Syndrome

Interventions

Type	Name	Description
DRUG	A-Phase: tirofiban; Z-Phase simvastatin
DRUG	Duration of Treatment: A-Phase: minimum suggested 48 hours, maximum suggested 108 hours. Z-Phase: 2 years
DRUG	Comparator: A-Phase: low molecular weight heparin, unfractionated heparin
DRUG	Duration of Treatment: A-Phase: low molecular weight heparin, 2 to 8 days; unfractionated heparin, minium suggested 48 hours, maximum 108 hours
DRUG	Duration of Treatment: Z-Phase, 2 years.

Timeline

• Start date: 1999-11-01
• Primary completion: 2004-03-23
• Completion: 2004-03-23
• First posted: 2005-11-10
• Last updated: 2024-08-15